Milestone (MIST) Q1 2026 Earnings Report Highlights CARDAMYST Launch and Financial Performance
Milestone Pharmaceuticals reported its first quarter of commercial sales for CARDAMYST, with $0.2 million in product revenue and over 400 unique prescribers. The company experienced a net loss of $26.1 million ($0.20 per share) compared to the prior year's period.
Tickers: $MIST
Topics: financial_performance pharmaceuticals product_launch